Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Benjamin Rains headshot

Here's How to Find Top-Ranked Stocks Under $10 to Buy

by Benjamin Rains

Here are 5 stocks of the over 30 highly-ranked stocks trading under $10 a share that made it through this week's screen...

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for August 19th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 19th

Zacks Equity Research

Will Catalyst Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Catalyst Pharmaceuticals.

Zacks Equity Research

Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 233.33% and 50.18%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.

Zacks Equity Research

Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.

Benjamin Rains headshot

Explosive Stocks Under $10

by Benjamin Rains

Let's start the second half of 2019 by searching for "cheap" stocks that look poised to surge...

Zacks Equity Research

Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

by Zacks Equity Research

Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.

Zacks Equity Research

Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.